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Introduction
Ipilimumab, an anti CTLA-4 monoclonal antibody, has been the first approved immunotherapy for metastatic melanoma [1] [2] [3] . Enterocolitis due to anti CTLA-4 is observed in 7%-22% of patients, and shares similarities with inflammatory bowel diseases [4, 5] .
Anti PD-1 antibodies are efficient to treat advanced melanoma [6] [7] [8] [9] , and other cancer types [10] [11] [12] [13] [14] . Diarrhoea or colitis occurs in 10% of patients treated with anti PD-1 (FDA registration data). A randomized trial of Nivolumab, Ipilimumab, or association of both, showed that combination therapy was more toxic than Ipilimumab and Nivolumab alone; in addition, diarrhoea and colitis were more frequent with Ipilimumab than with Nivolumab [7] .
There is a need for a more detailed description of these IrAE, in order to improve their recognition and treatment. The aim of the present study was to describe GI-IrAE in patients treated with anti-PD-1.
Methods-patients
This is an observational, retrospective cohort study. All consecutive adult patients who had a suspected GI-IrAE related to anti-PD-1 or anti-PD-L1 antibody between January 2013 and August 2016 were included. Patients were recruited through the pharmacovigilance registry (Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie; REISAMIC) of Gustave Roussy Cancer Center, or directly referred to the Gastroenterology departments of Bicêtre Hospital, Clermont Ferrand Hospital or Créteil hospital.
Gastrointestinal symptoms had to occur after initiation of anti-PD-1, and differential diagnoses (GI infection, tumour-related symptoms) had to be excluded [15] . Only patients with histological evidence of GI inflammation were diagnosed as having GI IrAE. Patients previously exposed to anti-CTLA-4 could be included in this analysis, but those who received anti-CTLA-4 and anti-PD-1 simultaneously were not included.
Methods-data collection
Clinical, biological and endoscopic data were collected from medical records and reviewed through a multidisciplinary approach with oncologists, gastroenterologists, pathologists, immunologists and a pharmacist specialized in pharmacovigilance. The causality between the anti-PD-1 antibody and the gastro-intestinal adverse event was assessed using the WHO-UMC system (Uppsala Monitoring Center). Incidence rate of GIIrAE related to anti-PD-1 or PDL-1 treatments was estimated, by dividing the number of patients with GI IrAE with the total number of patients who had received anti PD-1, both in Gustave Roussy. All concomitant therapies in the last 3 months before initiation of anti-PD-1 treatment and during the whole treatment period were collected.
Perendoscopic gastrointestinal biopsies were reviewed by a single pathologist (C. Mussini). Histological staining using haematoxylin eosin safran, and immunohistochemistry using anti-CD3 and anti-CD8 antibodies were carried out, when appropriate.
Methods-statistics
Quantitative data are described with the median (range) and qualitative data are described as numbers and percentages. Quantitative data were compared using Student's t-test and qualitative data using the v2 test or Fischer's exact test, when appropriate.
Methods-ethics
This study was approved by the ethics committee of Paris-Ile de France VII (PP 16-042).
Results

Study population
Forty-four patients were referred for suspected GI-IrAE associated with anti-PD-1 treatment (flow chart, Figure 1 ). Among them, 11 patients had tumour-related symptoms. Eight patients had mild diarrhoea, normal endoscopies and biopsies and spontaneous resolution of symptoms, despite continuation of anti-PD-1. Other differential diagnoses were opioid-induced constipation (n ¼ 1), radiation enteritis (n ¼ 1) and capillary leak syndrome (n ¼ 1). One patient refused endoscopy. Another patient died of a septic shock, unrelated to anti PD-1, shortly after admission. Therefore, 20 out of 44 (45%) patients were analysed. Causality in these patients was considered as certain in 13/20 (65%), likely in 6/20 (30%) and probable in 1/20 (5%) patients.
Incidence of GI-IrAE
Over the study period, patients were included from Gustave Roussy (n ¼ 13), Créteil (n ¼ 4), Foch (n ¼ 2) and Curie (n ¼ 1) oncology units. They were referred to the gastroenterology departments of Kremlin Bicêtre (n ¼ 15), Créteil (n ¼ 4) and Clermont-Ferrand hospitals (n ¼ 1). We estimated the incidence of confirmed GI-IrAE within the Gustave Roussy patients treated with anti PD-1, as 13/868 (1.5%). The proportion of confirmed GI-IrAE was not different between patients who had been exposed to anti-CTLA-4 and those who had not. Among the 13 patients treated in Gustave Roussy, 2/118 (1.8%) had received anti CTLA-4, before anti PD-1, whereas 11/778 (1.4%) had not (P ¼ 0.67). The two patients who had been exposed to anti CTLA-4 had a similar presentation and clinical course as those who were anti CTLA-4 naive.
Patients with GI-IrAE
The main clinical characteristics of the 20 patients are shown in Table 1 . Nineteen patients received anti-PD-1 treatment alone, while one patient received concomitant Dacarbazine for metastatic melanoma. Treatment was given according to local procedures or to clinical trials protocols. No patient had personal or familial history of Crohn's disease or ulcerative colitis. Two patients had prior exposition to anti-CTLA-4, without history of GI-IrAE.
Clinical features of GI-IrAE
Patients received a median of seven (1-33) infusions of anti-PD-1 before GI-irAE. Fourteen out of 20 patients (70%) had grade 3 or grade 4 GI-IrAE. The most frequent symptoms of GI-irAE were diarrhoea (18/20; 90%), abdominal pain (14/20; 70%), and nausea or vomiting (11/20; 55%). No patient had mouth ulcers, anal lesions or fever.
Endoscopic findings
Colonoscopy and flexible sigmoidoscopy. All patients had either a colonoscopy [carried out in 15/20 (75%) patients, including 12 with an ileoscopy] or a flexible sigmoidoscopy (5/20; 25%). Eight patients (40%) had a normal colonoscopy or sigmoidoscopy, while 12 patients had abnormal endoscopies. All the patients with abnormal lower GI endoscopy had at least one lesion accessible to a flexible sigmoidoscopy. Endoscopic lesions were localized as follows: 7/12 (58%) in the rectum, 10/12 (83%) in the descending colon, 6/9 (67%) in the transverse colon and 5/9 (56%) in the ascending colon. Terminal ileitis was observed in 1/12 (11%) patient. Extensive colitis was found in 4/12 (33%) patients. Three Flow chart of gastrointestinal immune-related adverse events (GI-IrAE). *Tumour-related symptoms included three patients with peritoneal carcinomatosis, six patients with intestinal metastases, one with uretero-rectal fistula, and one with metachronous colorectal carcinoma and radiation proctitis. 
Clinical subgroups of GI-IrAE patients
Acute colitis. Eight patients had an acute colitis. They had received 7 (1; 33) infusions of Nivolumab (n ¼ 3) or Pembrolizumab (n ¼ 5). All patients had diarrhoea, six had watery diarrhoea and two had bloody diarrhoea. Endoscopic findings included erythema (7/8), mucosal bleeding (2/8) and deep (1/8) or superficial (1/8) ulcerations. One patient had a normal flexible sigmoidoscopy. Upper GI endoscopy was either normal (1/7), or showed gastric erythema (3/7), oesophageal candidiasis (2/7) or gastric ulcerations (1/7). Colonic biopsies showed acute mucosal inflammation with neutrophils and cryptitis (8/8). Two patients had also chronic infiltration, including mucosal infiltration with lymphocytes and plasma cells as well as crypt branching, shortening and atrophy. Three patients had apoptosis of epithelial cells within the crypts. Gastric biopsies were carried out in four patients. One had a Helicobacter pylori-related gastritis, one had a non-specific gastritis and two had a lymphocytic gastritis (more than 30 intraepithelial lymphocytes per 100 epithelial cells). Duodenal biopsies were carried out in 4/8 patients; all had chronic inflammation (lymphocyte and plasma cell infiltrates), two had also neutrophil infiltration, two had a partial villus blunting and two had increased intraepithelial lymphocyte count. All eight patients with acute colitis were treated with systemic corticosteroids; seven of them (87.5%) achieved clinical remission. One patient failed to respond to corticosteroids, and subsequently received off label infliximab followed by vedolizumab, as an alternative to colectomy, with partial response. He died 3 months later from tumour progression.
Microscopic colitis. Seven patients had a microscopic colitis, including six with lymphocytic colitis, and one with collagenous colitis.
They had received six (2-19) infusions of Nivolumab (n ¼ 4) or Pembrolizumab (n ¼ 3). In the last 3 months before GI-IrAE, 4/7 patients (57%) had received proton pump inhibitors (PPIs), one had received serotonin reuptake inhibitor, and two had received NSAIDS (2/7). Diarrhoea did not improve after SRI and NSAIDS discontinuation. Patients could not discontinue PPI due to gastroesophageal reflux. All seven patients had watery diarrhoea (grade 2 in five); 2 of them had hypokalaemia.
All seven patients had a complete colonoscopy. It was macroscopically normal in 3/7 (43%) patients. The four other patients had erythema of the left and sigmoid colon; one patient had also superficial ulcerations at the recto-sigmoid junction. All seven patients had an upper GI endoscopy, which was normal in four (57%) cases. Two patients (29%) had gastric erythema and 1/7 (14%) had gastric erosions.
All patients had an increased count (>30/100 enterocytes) of CD3 þ CD8þ intraepithelial lymphocytes (supplementary Figure S1 , available at Annals of Oncology online); it was confined within the crypts in two of them. In addition, four patients also had a mucosal infiltration with neutrophils and cryptic abscesses. One patient had a collagenous colitis defined by a thickening of the basal collagenous layer of 40 micrometres associated with an increased count of CD3 þ CD8þ intraepithelial lymphocytes (>50/100 enterocytes). Ileal biopsies were carried out in four patients and showed intraepithelial lymphocytosis in three (>30/ 100 enterocytes). Gastric biopsies were either normal (5/7) or showed non-specific gastritis (2/7). Duodenal biopsies were normal in 5/7 patients or showed lymphocytic duodenitis (>30/100 enterocytes).
Three patients received budesonide (successful in two); four patients received systemic corticosteroids (successful in two). One patient received infliximab but did not respond. All seven patients stopped anti-PD-1 treatment because of the GI-irAE. Median time to resolution of diarrhoea was 98 days (42-226).
Inflammation of the upper gastrointestinal tract. Four patients had inflammation of the upper gastrointestinal tract. They had received nine (2-12) infusions of Nivolumab (n ¼ 2) or Pembrolizumab (n ¼ 2). Time to onset of GI-IrAE was 4.4 (0.9-7.4) months. No patient received NSAIDS. The four patients (100%) had nausea and anorexia, three had vomiting and one had dysphagia.
All four patients had an upper GI endoscopy and a complete colonoscopy. Upper GI endoscopy showed necrotic gastritis with poor gastric distensibility in two of four (supplementary Figure S2 , available at Annals of Oncology online), gastric erythema and normal endoscopy in one of four each. Colonoscopy was either normal (3/4) or showed patchy colonic erythema (1/4). Ileum was normal in all four patients. Gastric biopsies of the two patients with ulcerative and necrotic gastritis showed large necrosis of the epithelium, and an inflammatory infiltrate with neutrophils and lymphocytes. Duodenal biopsies were taken in three out of four patients with upper GI symptoms and showed partial villus blunting (n ¼ 2), intra-epithelial lymphocytosis (>30/100 enterocytes; n ¼ 2) and lymphocytic and plasma-cell infiltration of the lamina propria (n ¼ 2). The three patients with normal colonoscopies had normal colonic biopsies; the patient with colonic erythema had a lamina propria infiltration with lymphocytes and neutrophils.
Pseudo-obstruction. A 57-year-old patient with a metastatic, poorly differentiated metastatic neuroendocrine tumour, had nausea, epigastric pain, constipation, anorexia and vomiting after 5 months of treatment (11 infusions of Pembrolizumab). Treatment was withdrawn, as CT-scans showed small bowel and gastric distension. Upper GI endoscopy and flexible sigmoidoscopy were normal. Duodenal biopsies showed increased intraepithelial lymphocyte count (>30/100 epithelial cells) and mucosal infiltration with lymphocytes and plasma cells. Colonic biopsies showed chronic inflammation, including crypt disarray (branching, shortening and atrophy), lymphocytic and plasma cell infiltration of the lamina propria and apoptosis of the epithelial cells. There were no anti-neuronal or anti-enterocyte antibodies. Corticosteroids were ineffective. She received total parenteral nutrition for 3 months. She had an abrupt onset of fever, abdominal pain and abdominal distension. CT scan showed small bowel pneumatosis, aeroporty and no vascular enhancement of the intestinal wall (supplementary Figure S3 , available at Annals of Oncology online). She died of septic shock a few days later, 3 months after anti-PD1 treatment cessation.
Discussion
This study provides a description of GI-IrAE associated with anti-PD-1 treatment of cancer. It shows that, in half of the cases, GI symptoms are due to other diagnoses, particularly cancer progression. The rate of GI-IrAE was 1.5% in the present study. We observed four distinct clinical and pathological patterns of GI IrAE due to anti PD-1. Although less severe, acute colitis associated with anti-PD-1 share similarities with anti-CTLA-4-related colitis [4, 5] . Microscopic colitis has also been observed in some patients treated with anti CTLA-4 [4] and in one patient treated with anti PD-1 [16] , although it is not mentioned in a recent series of anti PD-1-induced GI IrAE [17] . Some of our patients with microscopic colitis had received drugs known to be associated with microscopic colitis, but they were taking them for a long time without diarrhoea, which appeared after they had received anti PD-1. Finally, upper GI tract lesions in the gastritis subgroup were severe, with necrosis and lymphoplasmocytic lamina propria expansion. There is overlap between the four categories of GI IrAE described in this paper. In patients with a predominating colonic inflammation, we found gastric and duodenal inflammation, particularly intraepithelial CD8þ lymphocytosis. Anti-PD-1 seems to induce widespread GI inflammation, but the clinical presentation might differ between patients according to the organ predominantly affected, colon or upper gastrointestinal tract. The clinical presentation of GI IrAE may result from the nature of the local antigen and its corresponding TCR, as it has been described in a Nivolumab-related myocarditis case [18] .
GI-IrAE associated with anti PD-1 appear to be more diverse and less frequent than those observed with anti CTLA-4. We found that the rate of confirmed, severe GI-IrAE was 1.5%. The reported rate of diarrhoea in patients treated with anti PD-1 is 10%. The difference between the rate of diarrhoea and that of confirmed severe GI-IrAE is most probably due to diarrhoea of other causes, and mild diarrhoea. Consistently, in a recent literature review, the rate of diarrhoea under anti-PD-1 has been reported to range from 10% to 15%, but diarrhoea and colitis leading to Nivolumab withdrawal have been reported to be of 2% and 1%, respectively [19] . PD-1 predominantly regulates effector T-cell activity in peripheral tissues dependent on PDL1/2 expression in non-immune cells, dendritic cells as well as T lymphocytes [20] , by promoting resolution of activation [21] and T-cell exhaustion phenotype [22] . It has been shown that the intensity of expression of PDL1 is associated with a benefit in the use of anti-PD1 in patients with non-small cell lung cancer [23] . In contrast, CTLA-4 is more broadly expressed, particularly on Foxp3 þ regulatory T lymphocytes in the lamina propria of the intestines and appears to have a specific role in the maintenance of intestinal homeostasis [24] . This difference in function could explain why GI-IrAE are more frequent and severe with anti-CTLA-4 than with anti-PD-1 antibodies.
This study may help to define guidelines about anti-PD-1-related GI-IrAE. When a GI-IrAE is suspected in a patient treated with anti-PD-1, the first step should be to rule out a differential diagnosis, particularly tumour-related symptoms and infections. Patients with grade 3, 4 or persisting grade 2 CTCAE GI toxicities, should be referred to a gastroenterologist, for upper and/or lower GI endoscopy with biopsies, depending on predominant symptoms. Systemic corticosteroids should be prescribed, along with suspension of the anti-PD-1 treatment in patients with severe and/or persistent GI toxicity. At this stage, data are insufficient to give any recommendation for patients who fail to respond to corticosteroids.
